Niagen Bioscience (NAGE) Aktienübersicht
Niagen Bioscience, Inc. ist ein biowissenschaftliches Unternehmen, das sich mit der Entwicklung von Produkten für gesundes Altern befasst. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
NAGE Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Niagen Bioscience, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$3.05 |
| 52-Wochen-Hoch | US$10.52 |
| 52-Wochen-Tief | US$2.87 |
| Beta | 2.1 |
| 1 Monat Veränderung | -10.03% |
| 3 Monate Veränderung | -20.78% |
| 1 Jahr Veränderung | -68.94% |
| 3 Jahre Veränderung | 91.82% |
| 5 Jahre Veränderung | -62.16% |
| Veränderung seit IPO | -72.89% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 29
NAGE: Longevity And GLP-1 Wellness Tailwinds Will Support Future Upside
Niagen Bioscience's analyst price target has been updated from $18.00 to $21.20 as analysts factor in recent Street research that highlights both tempered near term expectations and longer term support from trends in longevity, GLP-1 adoption, and cellular wellness demand. Analyst Commentary Recent Street research on Niagen Bioscience shows a mix of trimmed targets and fresh positive views, with bullish analysts still highlighting long term themes in longevity, GLP-1 adoption, and cellular wellness as key supports for the stock's investment case.
Narrative-Update • Jul 14
NAGE: Rare Disease Drug Designations Will Drive Future Longevity Upside
Analysts have reset their fair value estimate for Niagen Bioscience to $9.00 from $12.00, reflecting updated views on revenue growth, profit margins, and the long term opportunity in ingredients tied to longevity and cellular wellness trends. Analyst Commentary Analyst views on Niagen Bioscience are mixed, with the new US$9.00 fair value estimate broadly aligned with a recent price target from one supportive firm, while several bearish analysts have trimmed their expectations.Recent updates
Narrative-Update • Jul 29
NAGE: Longevity And GLP-1 Wellness Tailwinds Will Support Future Upside
Niagen Bioscience's analyst price target has been updated from $18.00 to $21.20 as analysts factor in recent Street research that highlights both tempered near term expectations and longer term support from trends in longevity, GLP-1 adoption, and cellular wellness demand. Analyst Commentary Recent Street research on Niagen Bioscience shows a mix of trimmed targets and fresh positive views, with bullish analysts still highlighting long term themes in longevity, GLP-1 adoption, and cellular wellness as key supports for the stock's investment case.Narrative-Update • Jul 14
NAGE: Rare Disease Drug Designations Will Drive Future Longevity Upside
Analysts have reset their fair value estimate for Niagen Bioscience to $9.00 from $12.00, reflecting updated views on revenue growth, profit margins, and the long term opportunity in ingredients tied to longevity and cellular wellness trends. Analyst Commentary Analyst views on Niagen Bioscience are mixed, with the new US$9.00 fair value estimate broadly aligned with a recent price target from one supportive firm, while several bearish analysts have trimmed their expectations.Narrative-Update • Jun 30
NAGE: Future Execution On Telehealth Platform Will Drive Upside Potential
Niagen Bioscience's analyst price target has been revised lower from $23.00 to $18.00 as analysts incorporate updated assumptions for revenue growth, profit margin, discount rate, and future P/E into their models. Analyst Commentary Bullish analysts following Niagen Bioscience are revisiting their models at a detailed level, adjusting assumptions for revenue growth, profit margins, discount rates, and future P/E multiples.
Narrative-Update • Jun 16
NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside
Niagen Bioscience's analyst price target has been reduced by a combined $5 across recent reports as analysts factor in updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples, while maintaining a fair value estimate of $12.60. Analyst Commentary Recent research on Niagen Bioscience highlights a mix of optimism about the company’s long term potential and caution around the assumptions that underpin the current fair value estimate of $12.60.Narrative-Update • Jun 02
NAGE: Core Demand And Injectables Will Support Future Buyback Driven Upside
Analysts have trimmed their average price target on Niagen Bioscience by $1 to $12.60, reflecting updated models that incorporate modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly lower future P/E multiple. Analyst Commentary Recent Street research around Niagen Bioscience centers on how updated models reconcile the current share price with revised assumptions for growth, profitability, and valuation multiples.Narrative-Update • May 14
NAGE: Core Demand And Injectables Will Drive Future Upside Potential
Niagen Bioscience's analyst price target has shifted from $13.60 to $12.60, as analysts adjust their models to slightly lower revenue growth, profit margin, and fair value assumptions while still highlighting ongoing demand in the core business and potential upside from the injectable segment. Analyst Commentary Recent research updates show a consistent pattern of price target reductions, with the latest move taking the blended target to US$12.60.Narrative-Update • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.Narrative-Update • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.Narrative-Update • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.Narrative-Update • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking AlphaAnalyseartikel • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...Analyseartikel • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...Analyseartikel • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...Narrative-Update • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.Analyseartikel • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Analyseartikel • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Analyseartikel • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...Analyseartikel • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...Analyseartikel • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...Analyseartikel • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
Neues Narrative • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.Analyseartikel • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...Analyseartikel • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...Aktionärsrenditen
| NAGE | US Personal Products | US Markt | |
|---|---|---|---|
| 7D | -13.6% | 3.2% | 2.7% |
| 1Y | -68.9% | -11.0% | 20.9% |
Rendite im Vergleich zur Industrie: NAGE unter dem Niveau der Branche US Personal Products , die im vergangenen Jahr eine Rendite von -11% erzielte.
Rendite vs. Markt: NAGE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.9 erzielte.
Preisvolatilität
| NAGE volatility | |
|---|---|
| NAGE Average Weekly Movement | 7.8% |
| Personal Products Industry Average Movement | 9.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: NAGE hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: NAGEDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1999 | 117 | Rob Fried | www.niagenbioscience.com |
Niagen Bioscience, Inc. ist ein biowissenschaftliches Unternehmen, das sich mit der Entwicklung von Produkten für gesundes Altern beschäftigt. Das Unternehmen ist in den Segmenten Verbraucherprodukte, Inhaltsstoffe und Pharmazeutika tätig. Es bietet fertige Nahrungsergänzungsprodukte, die seine proprietären Inhaltsstoffe enthalten, direkt an Verbraucher und Händler an; Nikotinamid-Adenin-Dinukleotid (NAD+), ein essentielles Coenzym, das den Zellstoffwechsel reguliert; und entwickelt und vermarktet proprietäre, auf Inhaltsstoffen basierende Technologien, einschließlich Niagen in Lebensmittelqualität und Niagen in pharmazeutischer Qualität, und liefert diese Inhaltsstoffe als Rohmaterial an die Hersteller von Verbraucherprodukten.
Niagen Bioscience, Inc.'s Grundlagenzusammenfassung
| NAGE grundlegende Statistiken | |
|---|---|
| Marktanteil | US$247.39m |
| Gewinn(TTM) | US$15.99m |
| Umsatz(TTM) | US$129.08m |
15.1x
Kurs-Gewinn-Verhältnis 1.9x
Kurs-Umsatz-VerhältnisIst NAGE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NAGE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$129.08m |
| Kosten der Einnahmen | US$46.16m |
| Bruttogewinn | US$82.92m |
| Sonstige Ausgaben | US$66.93m |
| Gewinn | US$15.99m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.20 |
| Bruttomarge | 64.24% |
| Nettogewinnspanne | 12.39% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich NAGE auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/10 22:33 |
| Aktienkurs zum Tagesende | 2026/08/10 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Niagen Bioscience, Inc. wird von 9 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |